OncoTargets and Therapy (Jul 2020)
Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context
Abstract
Sneha Gullapalli,1 Jordi Remon,2 Lizza EL Hendriks,3 Gilberto Lopes4 1Division of Pulmonary and Critical Care, University of Miami, Jackson Memorial Hospital, Miami, FL, USA; 2Department of Medical Oncology, Centro Integral Oncológico Clara Campal (HM-CIOCC), Hospital HM Delfos, HM Hospitales, Barcelona, Spain; 3Department of Pulmonary Diseases GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands; 4Divisions of Hematology and Medical Oncology, Departments of Medicine, Miller School of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USACorrespondence: Jordi RemonDepartment of Medical Oncology, Centro Integral Oncológico Clara Campal (HM-CIOCC), Hospital HM Delfos, HM Hospitales, Avinguda Vallcarca 151, Barcelona 08023, SpainTel +34 93 254 50 29Email [email protected]: Immune checkpoint inhibitors (ICIs) have transformed the therapeutic strategy and prognosis of advanced non-small cell lung cancer (NSCLC) patients. Nowadays, ICIs as monotherapy or in combination with chemotherapy are the standard of care treatment in advanced NSCLC, and in stage III, durvalumab (a programmed death ligand 1 inhibitor) is the unique drug approved as consolidation treatment after chemo-radiotherapy. This article reviews the pharmacological properties, clinical activity and safety of durvalumab as monotherapy or in combination with chemotherapy or other ICIs in the therapeutic strategy of NSCLC patients.Keywords: durvalumab, non-small cell lung cancer, PACIFIC, rechallenge, MYSTIC
